Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

作者：Elizabeth R. Plimack, Thomas Powles, V.P. Stus, Rustem Gafanov, Dmitry Nosov, Tom Waddell, B. Yа. Alekseev, Frédéric Pouliot, Bohuslav Melichar, Denis Soulières, Delphine Borchiellini, Raymond S. McDermott, Ihor Vynnychenko, Yen‐Hwa Chang, Satoshi Tamada, Michael B. Atkins, Chenxiang Li, Rodolfo F. Perini, L. Rhoda Molife, Jens Bedke, Brian I. Rini · 发表于：European Urology · 年份：2023 · DOI：10.1016/j.eururo.2023.06.006 · 被引用次数：145 · 研究领域：Renal cell carcinoma treatment、Renal and related cancers、Cancer Genomics and Diagnostics